18 HASIVIM STREET, PETACH TIKVA, L3
European Medicines Agency Validates Marketing Authorization Application for D-PLEX₁₀₀
Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities
Interim Condensed Consolidated Financial Statements as of June 30, 2026
Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Material disclosure
Announces Exclusive Partnership for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada
Amended and Restated 2012 Share Option Plan
Solicits Proxy for Annual and Extraordinary General Meeting of Shareholders on July 15, 2026
Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Notice of Exempt Offering of Securities
No filings found
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload